CD101 expression and function in normal and rheumatoid arthritis-affected human t cells and monocytes/macrophages

Journal of Rheumatology

Volumn 38, Issue 3, 2011, Pages 419-428

  Jovanovic, Dragan V ^a   Boumsell, Laurence ^b   Bensussan, Armand ^c   Chevalier, Xavier ^d   Mancini, Arturo ^a   Di Battista, John A ^a  

^a MCGILL UNIVERSITY   (Canada)

^b INSERM   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

CD101; Modulation; Monocytes macrophages; Rheumatoid arthritis; T cells

Indexed keywords

CD101 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DNA; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; LIPOPOLYSACCHARIDE; LYMPHOCYTE ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; PHOSPHOLIPID ANTIBODY; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL DIFFERENTIATION; CELL LINEAGE; CELL POPULATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY TEST; DNA SYNTHESIS; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; CELL LINE; CELL PROLIFERATION; CYTOKINES; HUMANS; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MONOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 79952432851     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100676     Document Type: Article

References (25)

1. Rivas A, Ruegg CL, Zeitung J, Laus R, Warnke R, Benike C, et al. V7, a novel leukocyte surface protein that participates in T cell activation. I. Tissue distribution and functional studies. J Immunol 1995;154:4423-33.
2. Russell GJ, Parker CM, Sood A, Mizoguchi E, Ebert EC, Bhan AK, et al. p126 (CDw10l), a costimulatory molecule preferentially expressed on mucosal T lymphocytes. J Immunol 1996;157:3366-74. (Pubitemid 126449148)
3. Gouttefangeas C, Jackuot S, Meffre E, Schmid M, Boumsell L, Bensussan A. Differential proliferative responses in subset of human CD28+ cells delineated by BB27 mAb. Int Immunol 1994;6:423-30. (Pubitemid 24087235)
4. Bouloc A, Boulland ML, Geissmann F, Fraitag S, Andry P, Teillac D, et al. CD101 expression by Langerhans cell histiocytosis cells. Histopathology 2000;36:229-32. (Pubitemid 30145249)
5. Ruegg C, Rivas A, Madani ND, Zeitung J, Laus R, Engleman EG. V7, a novel leukocyte surface protein that participates in T cell activation. II. Molecular cloning and characterization of the V7 gene. J Immunol 1995;154:4434-44.
6. Soares LR, Tsavaler L, Rivas A, Engleman EG. V7 (CD101) ligation inhibits TCR/CD3-induced IL-2 production by blocking Ca2+ flux and nuclear factor of activated T cell nuclear translocation. J Immunol 1998;161:209-17. (Pubitemid 28285525)
7. Soares LR, Rivas A, Tsavaler L, Engleman EG. Ligation of the V7 molecule on T cells blocks anergy induction through a CD28-independent mechanism. J Immunol 1997;159:1115-24. (Pubitemid 127484086)
8. Soares LR, Rivas A, Ruegg C, Engleman EG. Differential response of CD+ V7+ and CD4+ V7- T cells to T cell receptor-dependent signals: CD4+ V7+ T cells are co-stimulation independent and anti-V7 antibody blocks the induction of anergy by bacterial superantigen. Eur J Immunol 1997;27:1413-21. (Pubitemid 27254833)
9. Bouloc A, Bagot M, Delaire S, Bensussan A, Boumsell L. Triggering CD101 molecule on human cutaneous dendritic cells inhibits T cell proliferation via IL-10 production. Eur J Immunol 2000;30:3132-9.
10. Yamaji K, Ikegami H, Fujisawa T, Noso S, Nojima K, Babaya N, et al. Evidence for Cd101 but not Fcgr1 as candidate for type 1 diabetes locus, Idd10. Biochem Biophys Res Commun 2005;331:536-42. (Pubitemid 40602670)
11. Fernandez I, Zeiser R, Karsunky H, Kambham N, Beilhack A, Soderstorm K, et al. CD101 surface expression discriminates potency among murine FoxP3+ regulatory T cells. J Immunol 2007;179:2808-14.
12. Bennett S, Por SB, Stanley ER, Breit SN. Monocyte proliferation in a cytokine-free, serum-free system. J Immunol Methods 1992;153:201-12.
13. Vukmanovic-Stejic M, Vyas B, Gorak-Stolinska P, Noble A, Kemeny DM. Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes. Blood 2000;95:231-40. (Pubitemid 30017247)
14. Dileepan KN, Page JC, Li Y, Stechschulte DJ. Direct activation of murine peritoneal macrophages for nitric oxide production and tumor cell killing by interferon-gamma. J Interferon Cytokine Res 1995;15:387-94.
15. Raposo BR, Água-Doce AM, Pereira da Silva JA, Graça L, Souto-Carneiro MM. Disease amelioration in the K/BxN mouse model of spontaneous chronic arthritis after CD8 T cell depletion. Ann Rheum Dis 2010;69:A66.
16. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32. (Pubitemid 33070205)
17. Bach JF. Regulatory T cells under scrutiny. Nat Rev Immunol 2003;3:189-98. (Pubitemid 37323204)
18. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62. (Pubitemid 38680433)
19. Harty JT, Tvinnereim AR, White DW. CD8+ T cell effector mechanisms in resistance to infection. Annu Rev Immunol 2000;18:275-308. (Pubitemid 30365382)
20. Guidotti LG, Chisari FV. Cytokine-mediated control of viral infections. Virology 2000;273:221-7. (Pubitemid 30641363)
21. Zamoyska R. CD4 and CD8: modulators of T-cell receptor recognition of antigen and of immune responses? Curr Opin Immunol 1998;10:82-7.
22. Barry M, Heibein JA, Pinkoski MJ, Lee SF, Moyer RW, Green DR, et al. Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol Cell Biol 2000;20:3781-94. (Pubitemid 30314478)
23. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 2004;4:372-7. (Pubitemid 38987064)
24. Clark A, Dean J, Tudor C, Saklatvala J. Post-transcriptional gene regulation by MAP kinases via AU-rich elements. Front Biosci 2009;14:847-71.
25. Faour WH, He Y, He QW, de Ladurantaye M, Quintero M, Mancini A, et al. Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J Biol Chem 2001;276:31720-31.